Enliven Therapeutics ELVN Cash Flow Statement (2019-2026)

NASDAQ ELVN
$41.81 +0.56 (+1.36%)
As of: Oct 21, 2026 · 3:59 PM EDT
Reported Financials

Enliven Therapeutics Quarterly Cash Flow Statement

Periods 30 quarters
Latest Jun 2026

Enliven Therapeutics reported cash from operations of -$18.53M and free cash flow of -$18.63M for the quarter ended Jun 2026, down 8.6% year over year. This cash flow statement covers 30 quarters of results from Mar 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-13.65M-14.32M-8.67M-8.89M-10.55M-9.55M-14.72M-16.72M-20.77M-19.37M-22.74M-19.95M-23.16M-23.18M-28.54M-25.34M-20.15M-29.67M-23.63M-32.49M
Depreciation and DepletionDep. & Depletion
0.02M0.03M0.04M0.05M0.06M0.06M0.07M0.07M0.08M0.08M0.08M0.08M0.08M0.08M0.07M0.08M0.06M0.05M0.01M0.01M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.02M0.03M39.00M0.05M0.06M0.05M0.07M0.07M0.08M0.08M0.08M0.08M0.08M0.06M0.07M0.08M0.06M0.08M0.01M0.01M
Share-based CompensationStock Comp.
1.00M0.98M0.65M0.70M1.10M0.74M2.26M4.20M3.40M3.06M4.52M5.14M5.18M5.34M6.80M7.72M7.19M12.31M7.40M13.92M
Gains from Investment SecuritiesGains Investment
0.00M-0.01M-0.04M0.02M0.03M0.00M
Other non-cash itemsOther Non-Cash
0.01M0.23M0.08M0.08M0.08M0.08M0.08M0.09M0.09M0.09M0.09M0.09M0.13M
Change in Working Capital
Change in Account PayablesChange Payables
-0.15M-0.12M-1.56M0.59M1.36M0.02M0.49M-0.19M-1.59M-0.96M2.16M-1.60M-0.06M0.32M0.22M0.79M-1.02M0.83M-0.52M-1.50M
Change in Accured ExpensesChange Accured Exp.
0.43M0.16M-0.29M0.85M0.39M0.66M-2.85M1.10M4.64M4.78M-3.07M-0.25M4.35M-1.28M-2.50M0.01M0.81M1.18M-4.47M3.19M
Change in Other Operating AssetsOther Assets Change
-1.43M-0.74M0.54M0.43M0.54M0.08M6.09M-0.33M-0.34M-1.72M3.64M2.45M-0.78M-0.54M0.15M0.40M-0.14M0.69M-1.65M2.16M
Change in Other Operating LiabilitiesOther Liabilities Change
0.00M0.00M0.00M-0.23M-0.08M-0.08M-0.08M-0.08M-0.09M-0.07M-0.09M-0.09M-0.09M-0.10M-0.13M
Other Working Capital ChangesOther WC Changes
0.01M0.01M-0.04M-0.16M0.31M-6.09M0.33M0.11M1.64M-3.73M-2.53M0.70M0.45M-0.22M-0.49M0.05M-0.79M1.55M-2.29M
Cash from OperationsCash from Ops.
-10.90M-12.49M-10.36M-7.12M-6.45M-8.15M-20.84M-12.05M-15.89M-12.48M-23.36M-20.44M-12.19M-17.20M-24.13M-17.06M-13.28M-15.84M-19.29M-18.53M
Investing Activities
Capital ExpendituresCapex
0.19M0.30M0.01M0.10M0.03M0.09M0.02M0.01M0.02M0.00M0.02M0.02M0.14M0.00M0.10M
Change in Property, Plant and EquipmentChange in PP&E
-0.19M-0.30M-0.01M-0.10M-0.03M-0.09M-0.02M-0.01M-0.02M0.00M-0.02M-0.02M-0.14M0.00M-0.10M
Purchase of InvestmentsInvestments Purchased
22.23M17.79M151.43M75.53M41.30M56.78M120.83M56.62M116.52M59.23M240.19M71.86M75.52M65.84M560.16M
Sale and Maturity of InvestmentsInvestments Sold
13.40M3.30M5.47M6.48M-11.95M40.00M80.00M38.91M77.17M80.59M117.24M60.67M56.74M67.80M87.69M108.36M118.69M
Cash from Investing ActivitiesCash from Investing
-8.83M-14.49M-0.19M-0.30M-0.01M-0.10M-0.03M-151.52M-35.55M38.69M-17.89M-33.67M14.83M0.73M1.43M-183.59M-4.06M12.38M42.53M-441.57M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.15M0.57M0.01M0.01M163.04M-1.39M0.03M0.09M0.27M2.11M1.12M0.78M0.23M1.75M0.21M0.72M10.05M29.94M
Net Shares Issued and RepurchasedNet Shares Issued
0.15M0.57M0.01M0.01M163.04M-1.39M0.03M0.09M0.27M2.11M1.12M0.78M0.23M1.75M0.21M0.72M10.05M29.94M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.15M0.57M0.01M0.01M163.04M-1.39M0.03M0.09M0.27M2.11M1.12M0.78M0.23M1.75M0.21M0.72M10.05M29.94M
Other financing activitiesOther financing
-0.27M-0.01M74.40M-1.32M-0.10M
Cash from Financing ActivitiesCash from Financing
46.99M-0.01M0.41M0.01M0.16M-2.38M237.44M-2.82M-0.43M0.09M90.27M1.81M1.12M39.97M0.23M218.38M-0.37M0.62M10.05M463.42M
Additional items
Change in Cash
27.26M-26.99M-10.15M-7.42M-6.30M-10.62M216.57M-166.39M-51.87M26.29M49.02M-52.29M3.75M23.50M-22.47M17.73M-17.71M-2.84M33.29M3.32M
Ending Cash Balance
110.08M75.59M100.20M124.17M101.71M119.44M98.90M132.18M135.51M
Free Cash FlowFCF
-10.90M-12.49M-10.56M-7.43M-6.46M-8.25M-20.88M-12.14M-15.91M-12.50M-23.38M-20.44M-12.22M-17.20M-24.15M-17.20M-13.28M-15.84M-19.29M-18.63M
Net Cash FlowNCF
27.26M-26.99M-10.15M-7.42M-6.30M-10.62M216.57M-166.39M-51.87M26.29M49.02M-52.29M3.75M23.50M-22.47M17.73M-17.71M-2.84M33.29M3.32M

Enliven Therapeutics Cash Flow Statement API

Pull Enliven Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ELVN&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY